Ultomiris Favored for Approval in EU for AChR-positive Generalized MG
Ultomiris (ravulizumab) has been recommended for approval in the European Union (EU) as an add-on therapy for most adults with…
Articles by Patricia Inacio, PhD
High-intensity Rehab in Hospital Linked to Delayed Recovery in Study
Contrary to increasing evidence, high-intensity inpatient rehabilitation was not found, in a Japanese study, to speed the recovery of people…
Soliris Is Safe and Effective in Real-world Use, Small US Study Shows
Soliris (eculizumab) safely and rapidly led to clinical benefits in people with generalized myasthenia gravis (gMG) who are…
MG Symptoms Weigh on Life Quality, Particularly for Women
People with myasthenia gravis, particularly women, have a high symptom burden that considerably affects their health-related quality of…
Woman’s Repeat MG Flares Likely Due to Rare, Benign Heart Tumors
A woman with repeat myasthenia gravis (MG) flares was found to have several rare and benign tumors in…
In Very Rare Cases, MG May Worsen After COVID-19 Vaccination
The Pfizer-BioNTech and the Moderna mRNA COVID-19 vaccines may, in very rare cases, cause myasthenia gravis (MG) symptoms to…
Opdivo May Trigger Myasthenia Gravis, Case Report Indicates
Treatment with the immunotherapy Opdivo (nivolumab) may, in rare cases, trigger myasthenia gravis (MG), according to a Japanese case report. The…
Risk Factors for MG Exacerbations, Myasthenic Crises ID’d in Study
Disease severity at diagnosis and levels of self-reactive antibodies are independent risk factors for myasthenic crisis and disease exacerbations, a…
Case Report Shows MG May Occur With Rare Miller Fisher Syndrome
Myasthenia gravis (MG) may occur alongside Miller Fisher syndrome, another rare autoimmune disease also characterized by weakness of…
Ocular MG Progression Risk May Be Reduced With Immunosuppressants
Immunosuppressant medications significantly reduced the risk of ocular myasthenia gravis (MG), which affects only eye and eyelid muscles, progressing…